Samalin Investment Counsel, LLC Halozyme Therapeutics, Inc. Transaction History
Samalin Investment Counsel, LLC
- $222 Million
- Q3 2024
A detailed history of Samalin Investment Counsel, LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Samalin Investment Counsel, LLC holds 9,747 shares of HALO stock, worth $436,763. This represents 0.25% of its overall portfolio holdings.
Number of Shares
9,747
Previous 11,952
18.45%
Holding current value
$436,763
Previous $625,000
10.88%
% of portfolio
0.25%
Previous 0.3%
Shares
6 transactions
Others Institutions Holding HALO
# of Institutions
542Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$790 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$578 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$297 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$182 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$153 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.24B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...